Urinary Excretion of Acetylamantadine by Cancer Patients

Cancer Clinical Trial

Official title: Urinary Excretion of Acetylamantadine by Cancer Patients

Status Completed

Clinical Trial Summary

The investigators have determined that the drug amantadine hydrochloride is metabolized by acetylation by a specific enzyme named spermidine/spermine N-acetyltransferase (SSAT). This enzyme is increased in cancer cells. The investigators hypothesized that the amount of N-acetylamantadine excreted in urine during the first 12 hours after an oral dose would serve as a diagnostic biomarker for the presence of cancer in a human test subject.

Clinical Trial Description

When patients present to their physician with symptoms of cancer at a later stage of development, survival tends to be poorer. Earlier diagnosis of cancer is expected to provide improved survival of patients due to earlier treatment intervention. However, implementation of this screening process is impaired by access and by cost. A simple and inexpensive test would serve as a screening tool that could be safely repeated at regular intervals to identify persons for whom more expensive and less accessible diagnostic investigations might become more appropriately directed. The specificity for an enzyme that increases markedly in cancer tissue, and the ease of administration of an already licensed pharmaceutical prescription product, amantadine hydrochloride, would appear to provide promise of such a desirable screening test. ;

Related Conditions & MeSH terms

• Cancer

• NCT number: NCT00755898
• Study type: Interventional
• Source: University of Manitoba
• Status: Completed
• Phase: Phase 2
• Start date: December 2003
• Completion date: July 2008